Skip to main content
. Author manuscript; available in PMC: 2018 Mar 17.
Published in final edited form as: Expert Opin Orphan Drugs. 2017 Mar 17;5(4):355–368. doi: 10.1080/21678707.2017.1304212

Figure 1.

Figure 1

PI3K and RAS are activated by multiple growth factors in neuroblastoma tumors. This activation leads to cellular proliferation and has been associated with relapsed disease and poor outcomes. Multiple drugs (purple) are in clinical development which inhibit one or more of the proteins in these pathways and may help improve outcomes for patients with high-risk neuroblastoma.